» Articles » PMID: 22161416

Physical Training for McArdle Disease

Overview
Publisher Wiley
Date 2011 Dec 14
PMID 22161416
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: McArdle disease is a rare metabolic myopathy caused by a complete absence of the enzyme muscle glycogen phosphorylase. Affected people experience symptoms of fatigue and cramping within minutes of exercise and are at risk for acute muscle injury (rhabdomyolysis) and acute renal failure. If the first few minutes of exercise are paced, a 'second wind' will occur enabling exercise to continue. This is due to mobilisation and utilisation of alternative fuel substrates. Aerobic training appears to improve work capacity by increasing cardiovascular fitness.

Objectives: To assess the effects of aerobic training in people with McArdle disease.

Search Methods: We searched the Cochrane Neuromuscular Disease Group Specialized Register (11 January 2011), CENTRAL (2010, Issue 4), MEDLINE (January 1966 to January 2011) and EMBASE (January 1980 to January 2011).

Selection Criteria: All randomised and quasi-randomised controlled studies of aerobic exercise training in people of all ages with McArdle disease.

Data Collection And Analysis: Two authors identified possible studies for inclusion and assessed their methodological quality. Had more than one study of sufficient methodological quality been identified we would have undertaken a meta-analysis.

Main Results: There were no randomised or quasi-randomised controlled trials of aerobic training in people with McArdle disease. However, three open studies using small numbers of participants provided some evidence that aerobic training improves fitness without adverse events in people with McArdle disease.

Authors' Conclusions: Evidence from non-randomised studies using small numbers of patients suggest that it would be safe and worthwhile for larger controlled trials of aerobic training to be undertaken in people with McArdle disease.

Citing Articles

Late Presentation of McArdle's Disease Mimicking Polymyalgia Rheumatica: A Case Report and Review of the Literature.

Elghobashy M, Pohl U, Bateman J Case Rep Rheumatol. 2025; 2025:8148736.

PMID: 39803349 PMC: 11724029. DOI: 10.1155/crrh/8148736.


Toward an Understanding of GSD5 (McArdle disease): How Do Individuals Learn to Live with the Metabolic Defect in Daily Life.

Karazi W, Coppers J, Maas D, Cup E, Bloemen B, Voet N J Neuromuscul Dis. 2023; 11(1):103-116.

PMID: 38108358 PMC: 10789332. DOI: 10.3233/JND-230027.


Diagnosis and management of children with McArdle Syndrome (GSD V) in New South Wales.

Adams L, Selvanathan A, Batten K, van Doorn N, Thompson S, Mitchell A JIMD Rep. 2023; 64(5):327-336.

PMID: 37701325 PMC: 10494502. DOI: 10.1002/jmd2.12389.


Data from the European registry for patients with McArdle disease (EUROMAC): functional status and social participation.

Karazi W, Scalco R, Stemmerik M, Lokken N, Lucia A, Santalla A Orphanet J Rare Dis. 2023; 18(1):210.

PMID: 37488619 PMC: 10367320. DOI: 10.1186/s13023-023-02825-z.


Pretreatment of rhesus monkeys with transdermal patches containing physostigmine and procyclidine: implications of the delivery system for the potential application against VX nerve agent intoxication in humans.

Nam J, Kim M, Song Y, Kim C, Kim W, Yu C Arch Toxicol. 2023; 97(3):697-710.

PMID: 36633609 DOI: 10.1007/s00204-022-03438-4.